

CLARIFICATION TO ANNOUNCEMENTS OF 3 FEBRUARY 2020

MELBOURNE (AUSTRALIA) 5 February 2020: Invion Limited (ASX: IVX) ("Invion" or "Company") provides the following clarifications to announcements made 3 February 2020:

- ASX has asked the Company to confirm the term of the R&D Services Agreement signed with Pavay Biotech. The Agreement has an initial 12 month term. The parties may, by mutual agreement in writing, extend the Term for a further period of 12 months.
- The announcement regarding lapse of unlisted share options incorrectly stated that 259,860,927 IVXAT options remained on issue. This should have read 253,041,524 IVXAT options remain on issue.

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, The Cho Group, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.